AN2 Therapeutics (ANTX) Change in Accured Expenses (2021 - 2026)
AN2 Therapeutics (ANTX) reported Change in Accured Expenses of -$285000.0 for Q1 2026, up 30.66% year-over-year from -$218128.5 in Q1 2025, and up 84.11% quarter-over-quarter from -$1.8 million in Q4 2025.
AN2 Therapeutics (ANTX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Change in Accured Expenses data on file, last reported at -$285000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$285000.0, up 30.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.3 million (down 691.17% YoY), and the FY2025 annual result was -$2.4 million, down 7.86% from the prior year.
- Change in Accured Expenses advanced to -$285000.0 in Q1 2026 per ANTX's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.2 million in Q2 2023 and troughed at -$3.0 million in Q1 2024.
- A 5-year average of -$176235.3 and a median of -$267000.0 in 2022 frame the typical range for Change in Accured Expenses.
- On a YoY basis, Change in Accured Expenses climbed as much as 2018.75% in 2023 and fell as far as 394.19% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at $560000.0 in 2022, then plunged by 154.82% to -$307000.0 in 2023, then sank by 52.12% to -$467000.0 in 2024, then tumbled by 284.15% to -$1.8 million in 2025, then soared by 84.11% to -$285000.0 in 2026.
- Business Quant data shows ANTX's Change in Accured Expenses at -$285000.0 in Q1 2026, -$1.8 million in Q4 2025, and $892000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -285,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -285,000.00 |
| Mar 31, 2026 | -285,000.00 |
| Dec 31, 2025 | -1.79 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | 892,000.00 |
| Sep 30, 2025 | 892,000.00 |
| Jun 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Mar 31, 2025 | -411,000.00 |
| Mar 31, 2025 | -411,000.00 |
| Dec 31, 2024 | -467,000.00 |
| Dec 31, 2024 | -467,000.00 |
| Sep 30, 2024 | 418,000.00 |
| Sep 30, 2024 | 418,000.00 |
| Jun 30, 2024 | 845,000.00 |
| Jun 30, 2024 | 845,000.00 |
| Mar 31, 2024 | -3.02 Mn |
| Mar 31, 2024 | -3.02 Mn |
| Dec 31, 2023 | -307,000.00 |
| Dec 31, 2023 | -307,000.00 |